A Phase 2 interventional study of Toripalimab and Cytoreductive Nephrectomy in Immune Checkpoint Inhibitors, Cytoreductive Nephrectomy and Clear Cell Renal Cell Cancer (ccRCC), sponsored by RenJi Hospital. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-27.
Sponsored by RenJi Hospital · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing toripalimab in Carcinoma, Renal Cell — 8 open to participants now, 11 under way, 1 of them phase 3. toripalimab · Carcinoma, Renal Cell.
Among the 13 studies testing toripalimab in Carcinoma, Renal Cell, this one is the 11th largest by enrollment, is the only one that started in 2024, is one of 11 in phase 2, reaches primary completion later than 1 of the 10 other live ones, and was the 5th registered.
2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.
Browse Carcinoma, Renal Cell studies →8 of the 13 studies testing toripalimab in Carcinoma, Renal Cell are open now, in 1 country. Recruiting first, the newest first:
Hebei Medical University Fourth Hospital · Sites in China
Ages 18+
Jinling Hospital, China · Sites in China
Ages 18–80
Tianjin Medical University Second Hospital · Sites in China
Ages 18+
ZHOU FANGJIAN · Sites in China
Ages 18–80
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Sites in China
Ages 18–75
By country, each count listing its studies:
toripalimab: first FDA approval 2023 (LOQTORZI), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →
Of the 308 Carcinoma, Renal Cell studies recruiting now, 255 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2020; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 21 is below the median of 43 across 1,569 interventional studies indexed under Carcinoma, Renal Cell.
Median enrollment 40 across the 13 interventional studies. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 13 has an industry lead sponsor. The 9 most frequent:
RenJi Hospital is the lead sponsor of 551 studies on the registry; 248 are open to participants now.
21 studies in Carcinoma, Renal Cell by RenJi Hospital: 7 open now, 10 under way, none of them phase 3. Of 5 finished, 0 (0%) have results posted.
Among the 21 studies in Carcinoma, Renal Cell by RenJi Hospital, this one is the 13th largest by enrollment of the 15 interventional ones that give a count, is one of 5 that started in 2024, is one of 9 in phase 2, and was the 13th registered.
RenJi Hospital’s Carcinoma, Renal Cell studies by the year they started, since 2013.
1 of the studies testing toripalimab in Carcinoma, Renal Cell that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05768464The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolPostoperative Adjuvant Therapy for Non-clear Renal Cell Carcinoma With High-risk Recurrence Factors | 2026-12-30 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies testing toripalimab in Carcinoma, Renal Cell, from their registry updates:
Among RenJi Hospital’s 21 in Carcinoma, Renal Cell:
This tab as a report to print or save as PDF → With an account.
Study Objective: To determine the efficacy of upfront immune checkpoint inhibitors combined with deferred cytoreductive nephrectomy in treating metastatic renal cell carcinoma.
Primary Endpoint: Pathological Major Response (MPR), defined as the percentage of residual tumor ≦10% in the primary tumor after nephrectomy.
Study Design:
Population: Participants meeting the diagnostic criteria with biopsy-proven clear cell renal cell carcinoma. Clinical staging by CT or MRI demonstrating either any T, N1, M0 disease or any T, any N, M1 disease, together with at least one of the following: an IMDC score ≤3; or ≤5 metastatic lesions involving ≤3 organs.
Patient Grouping: Non-randomized.
Interventions: Eligible participants will receive upfront treatment with a combination of Axitinib and Toripalimab for 4 cycles. After 2 cycles of treatment, radiological assessment will be conducted using RECIST 1.1 criteria. If disease progression is observed, the clinical trial will be terminated, and second-line treatment will be initiated according to guidelines. If disease progression is not observed, treatment will continue for 2 additional cycles followed by repeat radiological assessment before undergoing surgery.
The criteria were revised on the registry on Oct 27, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Willingness to participate in the study and provision of written .
Male or female participants aged ≥18 years and \<80 years. confirmed clear cell renal cell carcinoma or renal cell carcinoma with a predominant clear cell component.
Clinical staging by CT or MRI demonstrating either any T, N1, M0 disease or any T, any N, M1 disease, together with at least one of the following: an IMDC score ≤3; or ≤5 lesions involving ≤3 organs.
A primary renal tumor, whether unilateral or bilateral, considered resectable. performance status of 0 or 1. No abnormalities in cardiac, bone marrow, hepatic, or renal function.
Willingness and ability to comply with study assessments and follow-up procedures.
Exclusion Criteria:
Non-clear cell carcinoma. Severe liver or kidney dysfunction, or other severe diseases. Immune deficiency, organ transplantation, or diseases. Severe central nervous system diseases. Other malignant tumors within the past 5 years, except for cured basal cell carcinoma of the skin and cervical carcinoma in situ.
Unable to comply with regular follow-up visits due to psychological, social, family, or geographical reasons.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Experimental arm
Drug: Toripalimab · Procedure: Cytoreductive Nephrectomy · Drug: Axitinib
Preoperative Treatment with Toripalimab: Administer 240mg of Toripalimab via intravenous infusion every 3 weeks for a total of 4 cycles.
Radical Nephrectomy: Complete resection of the tumor and affected kidney within the renal fascia. Partial Nephrectomy: Complete resection of the tumor while preserving maximal kidney function. Lymph Node Dissection: For patients with evident enlargement of retroperitoneal lymph nodes preoperatively, perform lymph node dissection at the renal hilum, along the ipsilateral major vessels, and anterior to the ipsilateral major vessels. Lymph node dissection is not required for patients without evident enlargement of retroperitoneal lymph nodes preoperatively.
Preoperative Treatment with Axitinib: Administer 5mg of axitinib orally twice daily for a duration of 3 months.
Pathological Major Response (MPR)
The percentage of residual tumor in the primary tumor after surgery, with MPR defined as ≦10% of residual tumor.
Time frame: through study completion, an average of 1 year
Plan to share: No
No publications or documents are linked to this record.
Ran from Mar 2024 to primary completion in Jun 2026, 27 months.
Of 185 non-industry phase 2 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 98. This study's 27 months is below that.
Counting every sponsor, half of 232 studies reached it within 58 months; a quarter within 33 and three quarters within 94.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: primary completion Mar 2026 → Jun 2026 and completion Mar 2029 → Jun 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Toripalimab · Axitinib